Developing therapeutics for cancers targeting driver mutations in epigenetic regulators is a challenging frontier in cancer therapy. A new study identifies a pathway that, when activated, inhibits the actions of the histone methyltransferase DOT1L in MLL fusion leukemia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Li, B.E. & Ernst, P. Exp. Hematol. 42, 995–1012 (2014).
Daigle, S.R. et al. Blood 122, 1017–1025 (2013).
Chen, C.-W. et al. Nat. Med. 21, 335–343 (2015).
Blander, G. & Guarente, L. Annu. Rev. Biochem. 73, 417–435 (2004).
Martínez-Redondo, P. & Vaquero, A. Genes Cancer 4, 148–163 (2013).
Vaquero, A. et al. Nature 450, 440–444 (2007).
van Leeuwen, F., Gafken, P.R. & Gottschling, D.E. Cell 109, 745–756 (2002).
Singh, S.K. et al. J. Exp. Med. 210, 987–1001 (2013).
Mishra, B.P. et al. Cell Rep. 7, 1239–1247 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Harte, P., Ernst, P. Harnessing gene repression to inhibit leukemia. Nat Med 21, 308–310 (2015). https://doi.org/10.1038/nm.3834
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3834